Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells are capable of differentiating into the multitude of cell types that compose the central and peripheral nervous systems and so have become the major focus of cell replacement therapies for the treatment of neurological disorders. Human embryonic stem cell (hESC) and human induced pluripotent stem cell (hiPSC)-derived cells have both been extensively studied as cell therapies in a wide range of neurodegenerative disease models in rodents and non-human primates, including Parkinson’s disease, stroke, epilepsy, spinal cord injury, Alzheimer’s disease, multiple sclerosis and pain. In this review, we discuss the latest progress made with stem cell therapies targeting these pathologies. We also evaluate the challenges in clinical application of human pluripotent stem cell (hPSC)-based therapies including risk of oncogenesis and tumor formation, immune rejection and difficulty in regeneration of the heterogeneous cell types composing the central nervous system.

Neuropathic pain causes severe suffering, and most patients are resistant to current therapies. A core element of neuropathic pain is the loss of inhibitory tone in the spinal cord. Previous studies have shown that foetal GABAergic neuron precursors can provide relief from pain. However, the source of these precursor cells and their multipotent status make them unsuitable for therapeutic use. Here, we extend these findings by showing, for the first time, that spinally transplanted, terminally differentiated human induced pluripotent stem cell-derived GABAergic (iGABAergic) neurons provide significant, long-term, and safe relief from neuropathic pain induced by peripheral nerve injury in mice. Furthermore, iGABAergic neuron transplants survive long term in the injured spinal cord and show evidence of synaptic integration. Together, this provides the proof in principle for the first viable GABAergic transplants to treat human neuropathic pain patients.

Low levels of DNA from an unidentified human source, often referred to as trace DNA, are ubiquitous, can be transferred onto objects by either direct or indirect methods and have an unknown longevity in situ. Clothing items from crime scenes are often submitted for trace DNA analysis, usually in attempt to identify a person of interest. This study examined the transfer of DNA onto three 10 × 10 cm areas located on the front, back and shoulder of an individual's external clothing (n = 300) during a regular day's activity. After wearing for a day, the DNA quantity on all three areas increased approximately 8-fold, which usually corresponded with an increase in the endogenous DNA from the wearer on the front area of the shirt. However, the back area of the shirt was more likely to demonstrate mixtures of endogenous and extraneous DNA. An additional study was also carried out to examine whether domestic laundering is a possible mechanism for the transfer of foreign DNA onto freshly laundered items and revealed that 74% of UV-treated cotton swatch samples produced DNA profiles after laundry with household garments. In summary, this study highlights the ease of DNA transfer onto an individual's external clothing during a regular day, and that extraneous DNA may be already on the clothing item prior to it being worn. The study provides empirical data to assist in the interpretation of trace DNA profiles and support a Bayesian approach to estimate statistical likelihoods for the transfer of foreign DNA. Graphical abstract ᅟ.

Skeletal muscle weakness is linked to many adverse health outcomes. Current research to identify new drugs has often been inconclusive due to lack of adequate cellular models. We previously developed a scalable monolayer system to differentiate human embryonic stem cells (hESCs) into mature skeletal muscle cells (SkMCs) within 26 days without cell sorting or genetic manipulation. Here, building on our previous work, we show that differentiation and fusion of myotubes can be further enhanced using the anabolic factors testosterone (T) and follistatin (F) in combination with a cocktail of myokines (C). Importantly, combined TFC treatment significantly enhanced both the hESC-SkMC fusion index and the expression levels of various skeletal muscle markers, including the motor protein myosin heavy chain (MyHC). Transcriptomic and proteomic analysis revealed oxidative phosphorylation as the most up-regulated pathway, and a significantly higher level of ATP and increased mitochondrial mass were also observed in TFC-treated hESC-SkMCs, suggesting enhanced energy metabolism is coupled with improved muscle differentiation. This cellular model will be a powerful tool for studying in vitro myogenesis and for drug discovery pertaining to further enhancing muscle development or treating muscle diseases.